Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr
Endpoints
Mon, 06/25/18 - 12:45 pm
Tags:
AbbVie, Rova-T, solid tumors, Calibr, CAR-T
Why is AbbVie’s tax rate so low? Humira patents cached in Bermuda: Reuters
Fierce Pharma
Wed, 06/20/18 - 07:10 pm
Tags:
AbbVie, taxes, Bermuda, Humira, patents
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
Wed, 06/20/18 - 09:26 am
Tags:
GSK2857916, GSK, brolucizumab, Novartis, aducanumab, Biogen, upadacatinib, AbbVie, VX-659 + tezacaftor + ivacaftor, Vertex Pharmaceuticals
Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win
Fierce Pharma
Mon, 06/18/18 - 09:47 pm
Tags:
Bristol-Myers Squibb, AbbVie, Empliciti, Multiple Myeloma
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Motley Fool
Wed, 06/13/18 - 10:16 am
Tags:
Humira, AbbVie, biosimilars
AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia
Endpoints
Mon, 06/11/18 - 09:17 am
Tags:
AbbVie, Roche, Venclexta, Rituxan, CLL, chronic lymphocytic leukemia
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
Sun, 06/10/18 - 10:59 am
Tags:
AbbVie, Huimra, Upadacitinib, rheumatoid arthritis
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Fri, 06/8/18 - 09:48 am
Tags:
Humira, AbbVie, Keytruda, Merck, Revlimid, Celgene, Opdivo, Bristol-Myers Squibb
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
Wed, 06/6/18 - 11:31 am
Tags:
AbbVie, Upadacitinib, rheumatoid arthritis, FDA, JAK inhibitors
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
Tue, 06/5/18 - 10:37 pm
Tags:
valrox, Biomarin, hepatitis A, risankizumab, AbbVie, Boehringer Ingelheim, psoriasis
#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless
Endpoints
Tue, 06/5/18 - 12:09 pm
Tags:
AbbVie, Rova-T, ASCO 2018, antibody-drug conjugate
ASCO18: AbbVie blood cancer combo off to a strong start in Phase 2
Biopharma Dive
Mon, 06/4/18 - 09:37 am
Tags:
AbbVie, Imbruvica, Venclexta, chronic lymphocytic leukemia, small lymphocytic lymphoma, ASCO 2018
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
Investors Business Daily
Fri, 06/1/18 - 10:43 pm
Tags:
AbbVie, Novartis, Humira, biosimilars, Europe, CHMP
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks
Fierce Pharma
Thu, 05/24/18 - 05:44 pm
Tags:
AbbVie, Imbruvica, CLL, Gazyva
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Wed, 05/23/18 - 09:54 am
Tags:
Pfizer, Xeljanz, AbbVie, Upadacitinib, JAK inhibitors, Amgen, Enbrel, Celgene
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
CP Wire
Tue, 05/22/18 - 09:53 am
Tags:
CytomX, AbbVie, CX-2029, cancer
Tue, 05/22/18 - 08:41 am
Tags:
CytomX, AbbVie, CX-2029
Amgen, AbbVie 'ahead of the crowd' in fighting payers' latest assault on copay coupons
Fierce Pharma
Mon, 05/21/18 - 09:18 am
Tags:
copay coupons, Amgen, AbbVie, payers
AbbVie bows to pressure to keep cheaper Imbruvica formula on the market
Fierce Pharma
Wed, 05/16/18 - 06:57 pm
Tags:
AbbVie, Imbruvica
AbbVie's elagolix could put pressure on budgets, ICER estimates
Biopharma Dive
Tue, 05/8/18 - 03:46 pm
Tags:
AbbVie, endometriosis, ICER, Elagolix

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.